DeepMed Research

Seagen Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1998-01-01

Employees: 3.2K

Market Cap: -

Website: http://www.seagen.com

Clinical Trials

FDG-PET to Investigate SGN-15 and Docetaxel in Patients With Advanced Non-Small Cell Lung Carcinoma

Phase 2

Completed

Conditions: Non-Small Cell Lung Carcinoma

First Posted Date: 2004-07-02

Last Posted Date: 2011-10-24

Lead Sponsor: Seagen Inc.

Target Recruit Count: 30

Registration Number: NCT00086333

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Providence Health System, Regional Cancer Program, Portland, Oregon, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 1 locations

Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma

Phase 2

Completed

Conditions: Anaplastic Large-Cell Lymphoma

First Posted Date: 2004-03-16

Last Posted Date: 2014-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 80

Registration Number: NCT00079755

Locations: 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
University of Califorinia at Los Angeles, Los Angeles, California, United States

and more 15 locations

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: SGN-40 (anti-huCD40 mAb)

First Posted Date: 2004-03-16

Last Posted Date: 2014-12-18

Lead Sponsor: Seagen Inc.

Target Recruit Count: 44

Registration Number: NCT00079716

Locations: 🇺🇸
The Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸
James R. Berenson M.D., Inc., West Hollywood, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

First Posted Date: 2003-06-27

Last Posted Date: 2011-10-24

Lead Sponsor: Seagen Inc.

Registration Number: NCT00028483

Locations: 🇺🇸
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States

A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

Phase 1

Completed

Conditions: Hodgkin Disease
Lymphoma, Large-Cell
Sarcoma, Kaposi
Lymphoma, T-Cell, Cutaneous
Lymphoma, B-Cell

First Posted Date: 2003-01-15

Last Posted Date: 2011-10-12

Lead Sponsor: Seagen Inc.

Target Recruit Count: 70

Registration Number: NCT00051597

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of Washington, Seattle, Washington, United States

and more 7 locations

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

Phase 2

Terminated

Conditions: Ovarian Neoplasms

First Posted Date: 2003-01-15

Last Posted Date: 2011-10-24

Lead Sponsor: Seagen Inc.

Target Recruit Count: 60

Registration Number: NCT00051584

Locations: 🇺🇸
California Hematology Oncology Medical Group, Torrance, California, United States
🇺🇸
Virginia Mason Medical Center, Seattle, Washington, United States
🇺🇸
Mountain States Tumor Institute, Boise, Idaho, United States

and more 3 locations

Safety/Efficacy Study of Immunoconjugate With Docetaxel in Non-small Cell Lung Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

First Posted Date: 2003-01-15

Last Posted Date: 2011-10-24

Lead Sponsor: Seagen Inc.

Target Recruit Count: 60

Registration Number: NCT00051571

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
Virginia Mason Research Center, Seattle, Washington, United States

and more 6 locations

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2002-02-28

Last Posted Date: 2011-10-24

Lead Sponsor: Seagen Inc.

Target Recruit Count: 160

Registration Number: NCT00031187

Locations: 🇺🇸
Bendheim Cancer Center, Greenwich, Connecticut, United States
🇺🇸
Arlington Fairfax Hematology-Oncology, P.C., Arlington, Virginia, United States
🇺🇸
Innovative Medical Research of South Florida, Miami Shores, Florida, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy